title: Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells.
abstract: BACKGROUND
  Large-volume leukapheresis (LVL) differs from normal-volume leukapheresis (NVL) by increased blood flow and altered anticoagulation regimen. LVL is now regarded as a safe procedure for collection of peripheral blood progenitor cells (PBPCs), but it is not known whether the procedure will alter CD34+ cell quality or will be useful for patients who mobilize few CD34+ cells into peripheral blood.
  
  
  METHODS
  The results from 82 LVL and 125 NVL (4.0-5.3 and 2.7-3.5 times the patients' blood volumes processed, respectively) were retrospectively analyzed in altogether 112 consecutive patients with malignant diseases.
  
  
  RESULTS
  The LVL yielded significantly more CD34+ cells (4.2 x 10(6) vs. 3.1 x 10(6)/kg, p = 0.006, all patients; and 1.8 x 10(6) vs. 1.3 x 10(6)/kg, p = 0.004, bad mobilizers) and significantly higher colony-forming units (77 x 10(4) vs. 33 x 10(4)/kg; all patients and 33 x 10(4) vs. 20 x 10(4)/kg, p < 0.001, both groups). Significantly fewer leukapheresis procedures were required to obtain 2 x 10(6) CD34+ cells per kg (one vs. two, p = 0.001, all patients; and two vs. three, p = 0.009, bad mobilizers). No significant differences in CD34+ cell viability and time to hematologic recovery were observed between the patients who received PBPCs harvested by NVL and LVL.
  
  
  CONCLUSIONS
  Although a median platelet loss of 36 percent can be expected, LVL can be recommended as the standard apheresis method for PBPC collections in patients with malignant diseases. LVL is particularly useful in patients who mobilize a low number of CD34+ cells into the peripheral blood.
authors.affiliation: Division of Hematology, Department of Medicine, The Blood Bank, Haukeland University Hospital, and the University of Bergen, Bergen, Norway. jenny.abrahamsen@helse-bergen.no
authors.forename: J F
authors.initials: JF
authors.lastname: Abrahamsen
authors.forename: S
authors.initials: S
authors.lastname: Stamnesfet
authors.forename: K
authors.initials: K
authors.lastname: Liseth
authors.forename: T
authors.initials: T
authors.lastname: Hervig
authors.forename: O
authors.initials: O
authors.lastname: Bruserud
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy; D013234:Stem Cells / Q000166:cytology* / Q000378:metabolism; D013736:Testicular Neoplasms / Q000628:therapy
chemical_list: D018952:Antigens, CD34